Straightforward Surgery Advances Drug Delivery To The Brain
This article was originally published in Start Up
Executive Summary
Adopting an established endoscopic nasal grafting technique, researchers at Mass Eye and Ear have shown the ability to deliver a drug across the blood-brain barrier effectively and with reduced side effects. Their work could move rapidly into clinical testing in neurodegenerative diseases and could form the basis for delivering a wide range of existing drugs as well as new compounds whose development is predicated on use of the technique.
You may also be interested in...
siRNA Opening Up CNS Device Opportunities
The neurodegenerative disease R&D collaboration between RNA interference specialist Alnylam and device maker Medtronic--the first siRNA-oriented convergence opportunity--appears to be inching closer to the clinic. Key to the program's success to date are refinements in the Medtronic catheter and infusion -pump system used to deliver the Alnylam compund, in keeping with Medtronic's strategic goal of better understanding the mechanics of delivering chronic drugs into the brain.
Through the Palace Walls: Blood-Brain Barrier Transport Technologies
Delivering compounds across the blood-brain barrier remains the rate limiting step in brain-drug development, yet the problem generally gets ignored until it's too late. Several biotechs are bringing novel strategies to finding a solution, focusing especially on brain cancers. Success may open the floodgates of CNS drug development.
Harbingers For IPF Drug Development
Roche’s decision to discontinue a Phase III program in idiopathic pulmonary fibrosis was the latest of several recent late-stage clinical failures, emblematic of the difficulty in finding new approaches to treat the disease.